or Try an Advanced Search...

    Technical Analysis for ELVN - Enliven Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 24.54 -3.42% -0.87
    ELVN closed down 3.42 percent on Friday, November 22, 2024, on approximately normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ELVN trend table...
    Date Alert Name Type % Chg
    Outside Day Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    50 DMA Resistance Bearish -3.50%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.50%
    Lower Bollinger Band Walk Weakness -3.50%
    Lower Bollinger Band Walk Weakness -6.26%
    Lower Bollinger Band Touch Weakness -6.26%
    Oversold Stochastic Weakness -6.26%
    NR7 Range Contraction -1.45%
    Lower Bollinger Band Walk Weakness -1.45%
    Older End-of-Day Signals for ELVN ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % 1 day ago
    Down 1% 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Possible NR7 1 day ago
    10 DMA Resistance 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ELVN Chart by TradingView
    Basic chart:

    Profile

    Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia

    Is ELVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02
    Nov 13 Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
    Nov 7 Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
    Oct 18 Why this largely unknown company is one analyst's top biotech pick
    Sep 30 Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial
    Sep 28 Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
    Sep 26 Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
    Sep 18 Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
    Sep 9 Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    Sep 4 Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
    See more ELVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 30.03
    52 Week Low 9.84
    Average Volume 284,583
    200-Day Moving Average 22.12
    50-Day Moving Average 26.53
    20-Day Moving Average 27.03
    10-Day Moving Average 25.64
    Average True Range 1.40
    RSI (14) 36.71
    ADX 23.96
    +DI 16.10
    -DI 22.46
    Chandelier Exit (Long, 3 ATRs) 25.59
    Chandelier Exit (Short, 3 ATRs) 27.90
    Upper Bollinger Bands 30.28
    Lower Bollinger Band 23.78
    Percent B (%b) 0.12
    BandWidth 24.07
    MACD Line -0.61
    MACD Signal Line -0.23
    MACD Histogram -0.3771
    Fundamentals Value
    Market Cap 1.01 Billion
    Num Shares 41.2 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -26.67
    Price-to-Sales 0.00
    Price-to-Book 2.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 27.14
    Resistance 3 (R3) 27.36 26.73 26.70
    Resistance 2 (R2) 26.73 26.07 26.61 26.56
    Resistance 1 (R1) 25.63 25.66 25.32 25.41 26.41
    Pivot Point 25.00 25.00 24.84 24.88 25.00
    Support 1 (S1) 23.90 24.34 23.59 23.68 22.67
    Support 2 (S2) 23.27 23.93 23.15 22.52
    Support 3 (S3) 22.17 23.27 22.38
    Support 4 (S4) 21.95